Developer docs
API playgroundTry for free, no card

Search company profiles

Purdue Pharma

Full company profile

uuid0000tbk

Namestring
Purdue Pharma
Legal namestring
Purdue Pharma L.P.
Company typeenum
Private
Founded yearint
1952
Descriptiontext

Purdue Pharma L.P. was a privately held, U.S.-domiciled pharmaceutical company headquartered in Stamford, Connecticut, that developed, manufactured, and marketed prescription medications and consumer health products. Founded in 1952 and controlled for decades by the Sackler family, the company became widely known for its opioid analgesic franchise, most notably OxyContin (launched 1996), which became one of the most prescribed opioid pain medications in the United States. Purdue also operated wholly-owned subsidiaries spanning biopharmaceutical R&D (Imbrium Therapeutics L.P.), CNS therapeutics (Adlon Therapeutics L.P.), biotech ventures (Greenfield BioVentures L.P.), and additional pharmaceutical product lines (Rhodes Pharmaceuticals L.P. and Purdue Pharmaceuticals L.P.). The company maintained a pre-dissolution workforce of 5,001–10,000 employees and distributed medicines through traditional pharmaceutical channels targeting pharmacies, hospitals, and healthcare providers.

The company's technology base centered on small-molecule drug development and formulation, with proprietary R&D concentrated in opioid analgesics, oncology, and CNS therapeutics. Its most notable pipeline asset at dissolution was tinostamustine, an investigational agent with dual mechanisms of action being evaluated in a registrational-intent Phase 2/3 adaptive platform trial (GBM AGILE) for glioblastoma in partnership with the Global Coalition for Adaptive Research (GCAR). As a prescription pharmaceutical manufacturer, Purdue derived revenue from drug sales through insurance providers, pharmacy benefit managers, and government healthcare programs, though specific pricing and revenue figures were never publicly disclosed.

Following its 2019 Chapter 11 filing, 2020 federal guilty plea, and 2026 sentencing to $5.5 billion in fines and forfeiture, Purdue permanently ceased operations on May 1, 2026 under a $7.4 billion bankruptcy settlement. The Sackler family contributed up to $7 billion over 15 years and relinquished all ownership in exchange for legal protections. The company's operations and remaining assets transitioned to Knoa Pharma LLC, a nonprofit entity owned by the Knoa Foundation, which will distribute former Purdue medicines at or below cost with a mandate focused on opioid abatement, overdose reversal agents, and opioid use disorder treatments.

Short descriptiontext

Purdue Pharma L.P. was a privately held U.S. pharmaceutical company that developed and marketed prescription medicines, notably the opioid analgesic OxyContin, until ceasing operations on May 1, 2026, when it was replaced by nonprofit successor Knoa Pharma LLC focused on opioid abatement.

Operating statusenum
Closed
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersStamford, United States
HQ citystring
Stamford
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
prescription pharmaceuticals, opioid analgesics, pain management, oncology drug development, pharmaceutical manufacturing
Industry3 codes
PRIMARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceuticals
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Technology or R&D, Personnel, Marketing or Sales, Others
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Purdue Pharma developed, manufactured, and marketed prescription medicines, primarily opioid analgesics anchored by OxyContin for managing severe pain, alongside a pipeline of CNS and oncology therapeutics (including the investigational glioblastoma agent tinostamustine). The company also operated several wholly-owned subsidiaries focused on biopharmaceutical research, CNS therapeutics, and bioventures. Following the May 1, 2026 dissolution, successor Knoa Pharma LLC distributes the former Purdue medicines, focusing on overdose reversal agents and opioid use disorder treatments at or below cost.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Purdue Pharma L.P. was a pharmaceutical company that developed and marketed prescription medicines, primarily opioid analgesics. The company's flagship product was OxyContin. As of May 1, 2026, Purdue Pharma permanently ceased operations following a $7.4 billion bankruptcy settlement related to opioid litigation. The company operated several subsidiaries including Imbrium Therapeutics L.P., Adlon Therapeutics L.P., Greenfield BioVentures L.P., Rhodes Pharmaceuticals L.P., and Purdue Pharmaceuticals L.P. Prior to dissolution, Purdue was developing tinostamustine, an investigational agent for glioblastoma through clinical trials.

Product and service2 records
1OxyContin
CategoryOpioid analgesic prescription drug
Description

Opioid analgesic medication for managing severe pain; Purdue Pharma's flagship branded prescription product that became one of the most prescribed opioid pain medications in the United States and the subject of extensive federal and civil litigation.

2Tinostamustine
CategoryInvestigational oncology drug
Description

Investigational pharmaceutical agent with dual mechanisms of action being developed as a potential first-in-class treatment for glioblastoma; currently in registrational-intent Phase 2/3 evaluation through the GBM AGILE adaptive platform trial.

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-08
Description

GCAR and Purdue Pharma L.P. announced the initiation of clinical evaluation of tinostamustine in the GBM AGILE trial, an international adaptive platform trial for patients with glioblastoma. The trial aims to assess the drug's effectiveness for newly diagnosed and recurrent glioblastoma, with a focus on innovative treatment approaches. Tinostamustine is a drug with dual mechanisms of action being developed as a potential first-in-class treatment for aggressive brain cancer.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1Endo International
TypeDirect peer
Description

Specialty pharmaceutical company historically concentrated in opioid pain management and CNS therapeutics, with overlapping exposure to opioid litigation and generic specialty pharma products. Highly comparable to Purdue's pain/CNS focus and legal trajectory.

TypeDirect peer
Description

Specialty pharmaceutical manufacturer with significant exposure to opioid pain products and CNS generics, also pursued bankruptcy restructuring amid opioid litigation. Directly comparable in product portfolio, regulatory exposure, and corporate restructuring profile.

TypeBroad incumbent
Description

Large generic and specialty pharmaceutical company with a CNS and pain management portfolio that overlaps with Purdue's product mix. Broader scale and geographic footprint make it a broad incumbent comparable rather than a direct niche competitor.

TypeBroad incumbent
Description

Diversified healthcare conglomerate with significant pharmaceutical operations in pain management and oncology, and one of the other major defendants in the broader opioid litigation landscape. Comparable as a broad incumbent in pharma with overlapping therapeutic categories.

TypeBroad incumbent
Description

Major pharmaceutical company with CNS and pain management franchises, including legacy opioid product exposure. Comparable as a broad incumbent operating in the same therapeutic categories Purdue served.

TypeBroad incumbent
Description

Global pharmaceutical leader with significant CNS and oncology pipelines, including active adaptive platform trial participation. Comparable in scale, R&D intensity, and clinical trial partnerships relevant to the tinostamustine GBM AGILE program.

TypeBroad incumbent
Description

Major pharmaceutical company with established CNS and pain therapeutic franchises plus a substantial oncology pipeline. Comparable as a broad incumbent with overlapping therapeutic area focus.

TypeRegional player
Description

Specialty biopharmaceutical company focused on opioid overdose reversal products (including naloxone-based treatments) — directly aligned with the successor Knoa Pharma mission of providing overdose reversal agents and opioid use disorder treatments.

TypeDirect peer
Description

Pharmaceutical company specializing in opioid use disorder treatments including buprenorphine-based therapies. Direct peer to the successor Knoa Pharma's addiction treatment portfolio and overlapping with Purdue's historical opioid franchise.

TypeEmerging player
Description

Developer of Narcan (naloxone nasal spray) for opioid overdose reversal; closely aligned with the mission Knoa Pharma has assumed from Purdue. Listed as legacy reference for the overdose reversal therapeutic category.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries5 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment7 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Purdue Pharma

Pharmaceuticalspurduepharma.com

Purdue Pharma L.P. was a privately held U.S. pharmaceutical company that developed and marketed prescription medicines, notably the opioid analgesic OxyContin, until ceasing operations on May 1, 2026, when it was replaced by nonprofit successor Knoa Pharma LLC focused on opioid abatement.

What Purdue Pharma does

Purdue Pharma L.P. was a privately held, U.S.-domiciled pharmaceutical company headquartered in Stamford, Connecticut, that developed, manufactured, and marketed prescription medications and consumer health products. Founded in 1952 and controlled for decades by the Sackler family, the company became widely known for its opioid analgesic franchise, most notably OxyContin (launched 1996), which became one of the most prescribed opioid pain medications in the United States. Purdue also operated wholly-owned subsidiaries spanning biopharmaceutical R&D (Imbrium Therapeutics L.P.), CNS therapeutics (Adlon Therapeutics L.P.), biotech ventures (Greenfield BioVentures L.P.), and additional pharmaceutical product lines (Rhodes Pharmaceuticals L.P. and Purdue Pharmaceuticals L.P.). The company maintained a pre-dissolution workforce of 5,001–10,000 employees and distributed medicines through traditional pharmaceutical channels targeting pharmacies, hospitals, and healthcare providers.

The company's technology base centered on small-molecule drug development and formulation, with proprietary R&D concentrated in opioid analgesics, oncology, and CNS therapeutics. Its most notable pipeline asset at dissolution was tinostamustine, an investigational agent with dual mechanisms of action being evaluated in a registrational-intent Phase 2/3 adaptive platform trial (GBM AGILE) for glioblastoma in partnership with the Global Coalition for Adaptive Research (GCAR). As a prescription pharmaceutical manufacturer, Purdue derived revenue from drug sales through insurance providers, pharmacy benefit managers, and government healthcare programs, though specific pricing and revenue figures were never publicly disclosed.

Following its 2019 Chapter 11 filing, 2020 federal guilty plea, and 2026 sentencing to $5.5 billion in fines and forfeiture, Purdue permanently ceased operations on May 1, 2026 under a $7.4 billion bankruptcy settlement. The Sackler family contributed up to $7 billion over 15 years and relinquished all ownership in exchange for legal protections. The company's operations and remaining assets transitioned to Knoa Pharma LLC, a nonprofit entity owned by the Knoa Foundation, which will distribute former Purdue medicines at or below cost with a mandate focused on opioid abatement, overdose reversal agents, and opioid use disorder treatments.

Purdue Pharma firmographics

Firmographics
Name
Purdue Pharma
Legal name
Purdue Pharma L.P.
Website
https://purduepharma.com
Company type
Private
Founded year
1952
Operating status
Closed
Headcount range
501–1,000 employees
Short description
Purdue Pharma L.P. was a privately held U.S. pharmaceutical company that developed and marketed prescription medicines, notably the opioid analgesic OxyContin, until ceasing operations on May 1, 2026, when it was replaced by nonprofit successor Knoa Pharma LLC focused on opioid abatement.
Ownership category
akta.pro rank

Purdue Pharma industry classification

Industry
Product category
Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Prescription pharmaceuticals
  • Opioid analgesics
  • Pain management
  • Oncology drug development
  • Pharmaceutical manufacturing

Where Purdue Pharma is headquartered

Location

Headquarters

HQ city
Stamford
HQ country
United States
HQ region
North America

Markets served

Purdue Pharma business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Operations, Technology or R&D, Personnel, Marketing or Sales, Others

Distribution channels1 record

Marketing channels1 record

Purdue Pharma product offering

Product offering

Core offering

Purdue Pharma developed, manufactured, and marketed prescription medicines, primarily opioid analgesics anchored by OxyContin for managing severe pain, alongside a pipeline of CNS and oncology therapeutics (including the investigational glioblastoma agent tinostamustine). The company also operated several wholly-owned subsidiaries focused on biopharmaceutical research, CNS therapeutics, and bioventures. Following the May 1, 2026 dissolution, successor Knoa Pharma LLC distributes the former Purdue medicines, focusing on overdose reversal agents and opioid use disorder treatments at or below cost.

Product overview

Purdue Pharma L.P. was a pharmaceutical company that developed and marketed prescription medicines, primarily opioid analgesics. The company's flagship product was OxyContin. As of May 1, 2026, Purdue Pharma permanently ceased operations following a $7.4 billion bankruptcy settlement related to opioid litigation. The company operated several subsidiaries including Imbrium Therapeutics L.P., Adlon Therapeutics L.P., Greenfield BioVentures L.P., Rhodes Pharmaceuticals L.P., and Purdue Pharmaceuticals L.P. Prior to dissolution, Purdue was developing tinostamustine, an investigational agent for glioblastoma through clinical trials.

Differentiator

Problem solved

Functional benefit

Products and services

  • OxyContin Opioid analgesic medication for managing severe pain; Purdue Pharma's flagship branded prescription product that became one of the most prescribed opioid pain medications in the United States and the subject of extensive federal and civil litigation.
  • Tinostamustine Investigational pharmaceutical agent with dual mechanisms of action being developed as a potential first-in-class treatment for glioblastoma; currently in registrational-intent Phase 2/3 evaluation through the GBM AGILE adaptive platform trial.

Companies that use Purdue Pharma

Customer profile

Ideal customer profiles3 records

Purdue Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Purdue Pharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Global Coalition for Adaptive Research (GCAR)coreStrategic or Co-development Partner · 8 April 2026GCAR and Purdue Pharma L.P. announced the initiation of clinical evaluation of tinostamustine in the GBM AGILE trial, an international adaptive platform trial for patients with glioblastoma. The trial aims to assess the drug's effectiveness for newly diagnosed and recurrent glioblastoma, with a focus on innovative treatment approaches. Tinostamustine is a drug with dual mechanisms of action being developed as a potential first-in-class treatment for aggressive brain cancer.

Recent moves7 records

Expansion highlights4 records

Purdue Pharma competitors and assessment

Company assessment

Direct peers

  • Endo International: Specialty pharmaceutical company historically concentrated in opioid pain management and CNS therapeutics, with overlapping exposure to opioid litigation and generic specialty pharma products. Highly comparable to Purdue's pain/CNS focus and legal trajectory.
  • Mallinckrodt Pharmaceuticals: Specialty pharmaceutical manufacturer with significant exposure to opioid pain products and CNS generics, also pursued bankruptcy restructuring amid opioid litigation. Directly comparable in product portfolio, regulatory exposure, and corporate restructuring profile.
  • Indivior: Pharmaceutical company specializing in opioid use disorder treatments including buprenorphine-based therapies. Direct peer to the successor Knoa Pharma's addiction treatment portfolio and overlapping with Purdue's historical opioid franchise.

Broad incumbents

  • Teva Pharmaceutical Industries: Large generic and specialty pharmaceutical company with a CNS and pain management portfolio that overlaps with Purdue's product mix. Broader scale and geographic footprint make it a broad incumbent comparable rather than a direct niche competitor.
  • Johnson & Johnson: Diversified healthcare conglomerate with significant pharmaceutical operations in pain management and oncology, and one of the other major defendants in the broader opioid litigation landscape. Comparable as a broad incumbent in pharma with overlapping therapeutic categories.
  • Allergan (now part of AbbVie): Major pharmaceutical company with CNS and pain management franchises, including legacy opioid product exposure. Comparable as a broad incumbent operating in the same therapeutic categories Purdue served.
  • Pfizer: Global pharmaceutical leader with significant CNS and oncology pipelines, including active adaptive platform trial participation. Comparable in scale, R&D intensity, and clinical trial partnerships relevant to the tinostamustine GBM AGILE program.
  • Eli Lilly: Major pharmaceutical company with established CNS and pain therapeutic franchises plus a substantial oncology pipeline. Comparable as a broad incumbent with overlapping therapeutic area focus.

Regional players

  • Emergent BioSolutions: Specialty biopharmaceutical company focused on opioid overdose reversal products (including naloxone-based treatments) — directly aligned with the successor Knoa Pharma mission of providing overdose reversal agents and opioid use disorder treatments.

Emerging players

  • Adapt Pharma (acquired by Emergent): Developer of Narcan (naloxone nasal spray) for opioid overdose reversal; closely aligned with the mission Knoa Pharma has assumed from Purdue. Listed as legacy reference for the overdose reversal therapeutic category.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights4 records

Customer concentration

Purdue Pharma social profiles

Digital presence

Purdue Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Purdue Pharma leadership team

Management profile

Number of profiles

Profiles4 records

Purdue Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries5 records

Purdue Pharma funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Purdue Pharma M&A and investment

M&A and investment

M&A1 record

Investments7 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Purdue Pharma

What does Purdue Pharma do?

Purdue Pharma developed, manufactured, and marketed prescription medicines, primarily opioid analgesics anchored by OxyContin for managing severe pain, alongside a pipeline of CNS and oncology therapeutics (including the investigational glioblastoma agent tinostamustine). The company also operated several wholly-owned subsidiaries focused on biopharmaceutical research, CNS therapeutics, and bioventures. Following the May 1, 2026 dissolution, successor Knoa Pharma LLC distributes the former Purdue medicines, focusing on overdose reversal agents and opioid use disorder treatments at or below cost.

Is Purdue Pharma a public or private company?

Purdue Pharma is a private company. It is classified as family owned and is currently closed.

When was Purdue Pharma founded?

Purdue Pharma was founded in 1952. It employs 501 to 1,000 people.

Where is Purdue Pharma based?

Purdue Pharma is headquartered in Stamford, United States, in the North America region.

Who are Purdue Pharma's main competitors?

Direct peers on record are Endo International, Mallinckrodt Pharmaceuticals and Indivior. Broad incumbents are Teva Pharmaceutical Industries, Johnson & Johnson, Allergan (now part of AbbVie), Pfizer and Eli Lilly. Emergent BioSolutions is listed as a regional player. Adapt Pharma (acquired by Emergent) is listed as an emerging player.

Does Purdue Pharma have an API?

No public API is recorded for Purdue Pharma.

What industry is Purdue Pharma in?

Purdue Pharma's product category is Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAN, Pain Management & Anesthesiology Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Real DealRichard Sackler poised to lose Greenwich home in opioid settlementA federal bankruptcy judge ruled that Purdue Pharma chair Richard Sackler cannot interfere with the sale of his Greenwich mansion, which was pledged as collateral for the $7.4 billion opioid settlement. The waterfront estate's sale proceeds would fund addiction treatment, and the judge noted eviction as a possible sanction. Sackler and his family will likely appeal the ruling.The National Law ReviewA Breakdown of Harrington v. Purdue Pharma L.P. in the Supreme CoThe Supreme Court ruled that bankruptcy code does not authorize a release and injunction that effectively discharges a nondebtor without consent. A Second Circuit case extended the automatic stay to a non-debtor for the life of a plan, distinguishing it from a discharge. The court cautioned that longer stays might be impermissible.YahooCinde Warmington can't escape her record on opioids: NH Sen. GannonNew Hampshire State Senator Bill Gannon argues that Cinde Warmington's record of lobbying Purdue Pharma and PainCare, a pill mill, makes her unfit for governor. He cites her campaign financing from PainCare and her repeated denials, contrasting her with Governor Ayotte's record.The Times of IndiaRichard Sackler and his wife tried to stop the sale of their Connecticut mansion, pledged toward Purdue Pharma's $7.4 billion opioid settlement; on October 28, a bankruptcy judge rejected both requestsOn October 28, a bankruptcy judge rejected Richard Sackler and Lin Gao's attempts to stop the sale of their Connecticut mansion, keeping it as pledged collateral for the $7.4 billion Purdue Pharma opioid settlement. The court said the sale must proceed, though the family remains in the home and may appeal.ReutersRichard Sackler loses bid to keep mansion despite Purdue settlementA US bankruptcy judge ruled that Richard Sackler and his wife must stop interfering with the sale of their Connecticut mansion to pay Purdue Pharma's $7.4 billion opioid settlement. The judge rejected their request to pause the sale, noting the home was sold internally to free $62 million. The couple plans to appeal the ruling.BeckershospitalreviewArizona sues PBMs over alleged role in opioid crisisArizona Attorney General Kris Mayes filed a consumer fraud lawsuit against Express Scripts and Optum, alleging their formulary and rebate practices contributed to the state's opioid epidemic. The suit accuses the PBMs of collaborating with Purdue Pharma to secure preferred formulary status for OxyContin in exchange for confidential payments. It seeks restitution, civil penalties, and injunctive relief.YahooNew Hampshire Gov. Kelly Ayotte is a hypocrite: MayerSusan Mayer argues Gov. Kelly Ayotte's ad calling Cinde Warmington an opioid lobbyist is false, citing Warmington's past representation of Purdue Pharma. Mayer notes Ayotte accepted $138,650 from PhRMA and supported Purdue Pharma lawyer Gordon MacDonald for attorney general and chief justice.WikipediaPhil Weiser: Difference between revisionsPhil Weiser, Colorado's attorney general since 2019, has pursued major settlements including over $912 million from Purdue Pharma and $1 million from Greystar. He also filed a PFAS lawsuit and released a report on Catholic clergy abuse, with settlements totaling $6.6 million.DrugPatentWatchStop Tracking Drug Patents. Start Tracking Who Controls Them.Purdue Pharma dissolved on May 1, 2026, with its OxyContin patents now held by Knoa Pharma, a nonprofit-owned successor. The article argues patent databases miss control changes like M&A carve-outs, bankruptcy, and royalty monetization, citing five cases including Bristol Myers Squibb's $74B Celgene deal and Allergan's tribe transfer.New York PostNJ towns ‘wasted’ $2.3M of opioid settlement on lavish purchases: ‘people are dying because of this’An investigation by NJ.com found that at least 25 New Jersey towns spent roughly $2.3 million of opioid settlement funds on items such as a $73,000 Mustang, monogrammed jackets and concerts, rather than addiction services. The $1.1 billion Purdue Pharma settlement, distributed through 2040, has left more than $53 million unspent in municipal accounts. Assemblyman Cody Miller plans legislation to tighten oversight.